| Journal | Fundamental & clinical pharmacology |
| Study Type | Observational Study |
| Population | Human participants |
This represents the largest systematic safety surveillance of medical cannabis in a regulated healthcare system, providing real-world adverse event data from over 3,000 patients in France’s national experimentation program. The findings establish baseline safety expectations for medical cannabis implementation at a population health level.
This observational study analyzed adverse drug reactions from France’s national medical cannabis registry over three years (2021-2024), encompassing 3,164 patients. Among participants, 37.5% experienced at least one adverse event, with 3% classified as serious adverse events including six acute coronary syndromes and eight cases of suicidal ideation. The most frequent adverse events were neurological (37.2%), gastrointestinal (16.9%), and psychiatric (15.2%). The study provides systematic pharmacovigilance data from a structured national program, though causality assessment and comparison to baseline rates in similar patient populations remain limited.
“These safety data align with what I observe clinically—cannabis is generally well-tolerated but not without risk, particularly for cardiovascular and psychiatric vulnerabilities. The 3% serious adverse event rate provides helpful context for informed consent discussions, though we must interpret these events within the context of underlying patient comorbidities.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How common are adverse drug reactions with medical cannabis?
- What are the most frequent side effects of medical cannabis?
- Are there cardiovascular risks associated with medical cannabis?
- What psychiatric risks should be monitored with medical cannabis use?
- Should medical cannabis be avoided in patients with psychiatric history?
FAQ
How common are adverse drug reactions with medical cannabis?
In this French registry study of 3,164 patients, 37.5% experienced at least one adverse drug reaction (ADR) during medical cannabis use. Only 3% of patients experienced serious adverse drug reactions, suggesting that while ADRs are relatively common, most are mild to moderate in severity.
What are the most frequent side effects of medical cannabis?
The most common adverse reactions were neurological (37.2%), gastrointestinal (16.9%), and psychiatric (15.2%). This pattern aligns with cannabis’s known effects on the central nervous system and digestive tract through cannabinoid receptors.
Are there cardiovascular risks associated with medical cannabis?
Yes, six cases of acute coronary syndromes were reported among the serious adverse events in this study. Clinicians should exercise caution when prescribing medical cannabis to patients with existing cardiovascular conditions or risk factors.
What psychiatric risks should be monitored with medical cannabis use?
Eight cases of suicidal thoughts, including one suicide attempt, were reported as serious adverse events. Half of these psychiatric events occurred in patients with pre-existing psychiatric conditions, highlighting the need for careful monitoring in vulnerable populations.
Should medical cannabis be avoided in patients with psychiatric history?
While not necessarily contraindicated, extra caution is warranted as 50% of serious psychiatric adverse events occurred in patients with pre-existing psychiatric conditions. Close monitoring and careful risk-benefit assessment are essential when considering medical cannabis in this population.